

Technology Advisory Committee A Interests Register

Topic: Pembrolizumab with lenvatinib for previously treated advanced, metastatic, or recurrent endometrial cancer [ID3811]

Publication Date: 21/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Susan Lalondrelle	Clinical expert	Indirect	Dr Lalondrelle is conducting research on the use of pembrolizumab for other treatment indications (endometrial and other cervix cancer).	-	03.10.2022	-	It was agreed her declaration would not prevent Dr Lalondrelle from providing expert advice to the committee.
Dr James Fotheringham	Committee member	Financial	Dr Fotheringham has conducted a scoping review on barriers of digital technologies for dialysis for Baxter Healthcare, all fees were paid to his employer.	-	19.12.2022	-	It was agreed that his declaration would not prevent Dr James Fotheringham from participating in discussions on this appraisal